129 related articles for article (PubMed ID: 9449161)
1. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A.
Lauerma AI; Surber C; Maibach HI
Skin Pharmacol; 1997; 10(5-6):230-4. PubMed ID: 9449161
[TBL] [Abstract][Full Text] [Related]
2. Topical FK506--clinical potential or laboratory curiosity?
Lauerma AI; Maibach HI
Dermatology; 1994; 188(3):173-6. PubMed ID: 7514460
[TBL] [Abstract][Full Text] [Related]
3. Strain-specific differences in the effects of cyclosporin A and FK506 on the survival and regeneration of axotomized retinal ganglion cells in adult rats.
Cui Q; Hodgetts SI; Hu Y; Luo JM; Harvey AR
Neuroscience; 2007 May; 146(3):986-99. PubMed ID: 17408862
[TBL] [Abstract][Full Text] [Related]
4. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A.
Bauer S; Brockmöller J; Kewitz H; Roots I
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):540-2. PubMed ID: 1283385
[TBL] [Abstract][Full Text] [Related]
5. Conversion from cyclosporin A to tacrolimus in pediatric liver transplantation.
Furlan V; Debray D; Fourre C; Taburet AM
Pediatr Transplant; 2000 Aug; 4(3):207-10. PubMed ID: 10933321
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.
Pawarode A; Shukla S; Minderman H; Fricke SM; Pinder EM; O'Loughlin KL; Ambudkar SV; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):179-88. PubMed ID: 17031644
[TBL] [Abstract][Full Text] [Related]
7. Uptake and metabolism of cyclosporin A and SDZ IMM 125 in the human in vitro skin2 dermal and barrier function models.
Vickers AE; Biggi WA; Dannecker R; Fischer V
Life Sci; 1995; 57(3):215-24. PubMed ID: 7596228
[TBL] [Abstract][Full Text] [Related]
8. Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants.
Yamamoto S; Kato R
J Dermatol Sci; 1994 Jul; 7 Suppl():S47-54. PubMed ID: 7528050
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells.
Pompeo A; Baldassare M; Luini A; Buccione R
Life Sci; 1999; 64(10):837-46. PubMed ID: 10096434
[TBL] [Abstract][Full Text] [Related]
10. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines.
Rifai N; Chao FF; Pham Q; Thiessen J; Soldin SJ
Clin Biochem; 1996 Apr; 29(2):149-55. PubMed ID: 8601324
[TBL] [Abstract][Full Text] [Related]
11. The role of testosterone in cyclosporine-induced osteopenia.
Bowman AR; Sass DA; Dissanayake IR; Ma YF; Liang H; Yuan Z; Jee WS; Epstein S
J Bone Miner Res; 1997 Apr; 12(4):607-15. PubMed ID: 9101372
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.
Billich A; Aschauer H; Aszódi A; Stuetz A
Int J Pharm; 2004 Jan; 269(1):29-35. PubMed ID: 14698574
[TBL] [Abstract][Full Text] [Related]
13. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro.
Batten P; McCormack AM; Page CS; Yacoub MH; Rose ML
Transplantation; 1999 Nov; 68(10):1552-60. PubMed ID: 10589954
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory therapy in ophthalmology - is there a place for topical application?
Bertelmann E; Pleyer U
Ophthalmologica; 2004; 218(6):359-67. PubMed ID: 15564752
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
Kim ST; Jang DJ; Kim JH; Park JY; Lim JS; Lee SY; Lee KM; Lim SJ; Kim CK
Pharmazie; 2009 Aug; 64(8):510-4. PubMed ID: 19746839
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures.
Igarashi K; Hirotani H; Woo JT; Stern PH
Bone; 2004 Jul; 35(1):47-56. PubMed ID: 15207740
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.
Cho CS; Chang Z; Elkahwaji J; Scheunemann TL; Manthei ER; Colburn M; Knechtle SJ; Hamawy MM
Int Immunol; 2003 Nov; 15(11):1369-78. PubMed ID: 14565935
[TBL] [Abstract][Full Text] [Related]
18. The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats.
Yigitaslan S; Erol K; Cengelli C
Adv Clin Exp Med; 2016; 25(2):237-42. PubMed ID: 27627555
[TBL] [Abstract][Full Text] [Related]
19. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level.
Andersson J; Nagy S; Groth CG; Andersson U
Immunology; 1992 Jan; 75(1):136-42. PubMed ID: 1371491
[TBL] [Abstract][Full Text] [Related]
20. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus.
Ericzon BG; Eusufzai S; Söderdahl G; Duraj F; Einarsson K; Angelin B
Transplantation; 1997 Jan; 63(1):74-80. PubMed ID: 9000664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
